Mirvaso (Galderma Laboratories, L.P.)
Welcome to the PulseAid listing for the Mirvaso drug offered from Galderma Laboratories, L.P.. This Adrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Galderma Laboratories, L.P. |
| NON-PROPRIETARY NAME: | brimonidine tartrate |
| SUBSTANCE NAME: | BRIMONIDINE TARTRATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Adrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC] |
| ROUTE: | TOPICAL |
| DOSAGE FORM: | GEL |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2013-08-23 |
| END MARKETING DATE: | 0000-00-00 |
Mirvaso HUMAN PRESCRIPTION DRUG Details:
| Item Description | Mirvaso from Galderma Laboratories, L.P. |
| LABELER NAME: | Galderma Laboratories, L.P. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 5(mg/g) |
| START MARKETING DATE: | 2013-08-23 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0299-5980_2c78b1f4-5ebf-4e6f-8b3d-c4d2dc6546e2 |
| PRODUCT NDC: | 0299-5980 |
| APPLICATION NUMBER: | NDA204708 |
Other BRIMONIDINE TARTRATE Pharmaceutical Manufacturers / Labelers:
